Pre-clinical Evaluation of the LSD1 Inhibitor HCI-2509: Defining the Biomarkers of Sensitivity and the Mechanisms of Resistance

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1111032

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Despite aggressive multi-modal treatment strategies, limited progress in the treatment of Ewing sarcoma (paediatric bone malignancy), has been achieved over the past 30 years. As such, the advent of novel and targeted therapeutics with favourable efficacy/toxicity profiles are eagerly awaited. This proposal will investigate the therapeutic utility of LSD1 inhibition as a treatment for Ewing sarcoma and the underlying mechanisms of sensitivity/resistance to this unique agent.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $340,068.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cell death | mutation analysis | resistance | sarcoma | xenografts

Related Links